Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of co-administered dalteparin sodium and alteplase on clinical and biochemical parameters in postpartum patients with lower extremity deep venous thrombosis

Xiuwu Liu¹, Gang Yu², Xiaohong Lai¹, Dan Lin¹

¹Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province 350001, China; ²Department of Gynecology, Jiangxi provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi Province 330006, China.

For correspondence:- Dan Lin Email: lindan_dr@163.com Tel:+8615959195038

Accepted: 30 June 2023 Published: 31 July 2023

Citation: Liu X, Yu G, Lai X, Lin D. Effect of co-administered dalteparin sodium and alteplase on clinical and biochemical parameters in postpartum patients with lower extremity deep venous thrombosis. Trop J Pharm Res 2023; 22(7):1475-1481 doi: 10.4314/tjpr.v22i7.17

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the clinical efficacy of co-administration of dalteparin sodium and alteplase in the treatment of postpartum lower extremity deep venous thrombosis.

Methods: A total of 88 patients with postpartum lower extremity deep venous thrombosis admitted to Jiangxi Provincial People's Hospital of The First Affiliated Hospital of Nanchang Medical College, Nanchang, China from January 2020 to December 2022 were enrolled in this study and divided into study group (treated with dalteparin sodium and alteplase) and control group (treated with alteplase only), with 44 patients in each group. Clinical parameters (limb circumference, pigmentation and ulcer area), hemorheological parameters [D-Dimer (D_D), fibrinogen (FIB), centipoise (CP), red cell assembling index (RCAI)], inflammatory factors (hs-CRP, IL-6, THF-a, NMP-9) and cell adhesion factors {platelet endothelial cell adhesion molecule-1 (PECAM-1) and vascular cell adhesion molecule 1 (VCAM-1)} were determined and recorded.

Results: Post-treatment, all the clinical and biochemical parameters in the study group were significantly improved compared with pre-treatment levels and the respective levels in the control group (p < 0.05). The overall response rate (ORR) in the study group was 95.45 %, which was higher than the 79.55 % for the control group (p < 0.05).

Conclusion: Concomitant administration of dalteparin sodium and alteplase is more efficacious than treatment of with alteplase alone in the management of postpartum lower extremity deep venous thrombosis. However, further clinical trials on this combination therapy is required for the validation of findings obtained in this work.

Keywords: Dalteparin sodium, Alteplase, Postpartum lower extremity deep venous thrombosis, Hemorheology, Cell adhesion factor